- Home
- ACTG vs LXEO Comparison
ACTG vs LXEO Comparison
Compare ACTG & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACTG | LXEO |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | |
| Sector | Miscellaneous | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.9M | 447.6M |
| IPO Year | 1995 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ACTG | LXEO |
|---|---|---|
| Price | $4.66 | $4.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $6.00 | ★ $18.44 |
| AVG Volume (30 Days) | 225.1K | ★ 653.8K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 161.11 | 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,004,000.00 | $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.12 | $2.51 |
| 52 Week High | $5.27 | $10.99 |
Technical Indicators
Market Signals| Indicator | ACTG | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 38.67 | 30.15 |
| Support Level | $4.51 | $4.41 |
| Resistance Level | $5.20 | $5.11 |
| Average True Range (ATR) | 0.15 | 0.38 |
| MACD | -0.04 | -0.13 |
| Stochastic Oscillator | 11.83 | 3.12 |
Price Performance
Historical ComparisonAbout ACTG Acacia Research Corporation (Acacia Tech)
Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations and Manufacturing Operations. It derives revenue from Intellectual Property Operations segment. Geographically, it operates in Americas, Europe, Middle East and Africa, China, India, and Asia-Pacific, excluding China and India.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.